Benefits
Reduced abdominal fat in one 12-week trial
In one 12-week trial in 95 healthy overweight adults, Sinetrol-XPur reduced abdominal fat by 9.73% compared with 3.18% on placebo, alongside basic dietary advice. The differences reported in that trial were in abdominal fat and in waist and hip circumference rather than in body weight or BMI. A much smaller 20-person study reported body fat down 15.6% and weight down 5.2 kg, but with only 10 people per group and no clearly described placebo control, those are very large numbers from very few people and should not be taken at face value.
Reduced waist and hip circumference versus placebo
In the 95-person, 12-week trial, waist circumference fell 5.71% compared with 1.56% on placebo (p<0.0001) and hip circumference fell 4.71% compared with 1.35%. This is a single manufacturer-funded trial, and the pattern fits modest changes in body shape rather than dramatic standalone weight loss.
Increased fat release in isolated human fat cells (laboratory work)
In isolated human fat cells in the laboratory, Sinetrol inhibited an enzyme called cAMP-phosphodiesterase by 97% and increased fat release about six-fold compared with untreated cells. This is test-tube work, not something measured inside the body, and it is offered as a proposed explanation for the changes seen in the human trial rather than as proof of how it works in people.
Shifted inflammation and oxidative blood markers in one trial
In the 95-person, 12-week trial, C-reactive protein (a marker of inflammation) fell 22.87% while it rose 61% in the placebo group, fibrinogen fell 19.93%, malondialdehyde fell 14.03%, and the antioxidant markers superoxide dismutase and glutathione rose 17.38% and 4.63% (all p<0.01). These are blood markers, not health outcomes, and in the same trial cholesterol and the other lipid measures did not change.
Mechanism of action
cAMP-phosphodiesterase inhibition
In laboratory tests on isolated human fat cells, the citrus polyphenols in Sinetrol blocked an enzyme called cAMP-phosphodiesterase. That keeps a cell signal called cAMP high, which switches on the machinery that breaks stored fat down into fatty acids. This has been shown in cells in a dish, not measured directly in people.
Adenosine receptor modulation by caffeine
Caffeine from guarana blocks adenosine receptors on fat cells, which normally hold fat breakdown in check. This is a proposed contribution based on how caffeine behaves in general. The trials tested the whole blend, so how much of any effect comes from the caffeine rather than the citrus polyphenols is unknown.
Antioxidant polyphenol activity
Naringin, hesperidin, and the anthocyanins from the blood orange and grapefruit components neutralise reactive oxygen molecules in laboratory tests, which may be why inflammation and oxidative blood markers shifted in the 12-week trial. Cholesterol and the other lipid measures were unchanged in that trial, so this should not be read as a broader heart or metabolic benefit.
Clinical trials
Randomised, double-blind, placebo-controlled trial of Sinetrol-XPur versus placebo in 95 healthy overweight adults (47 on Sinetrol-XPur, 48 on placebo), taken twice daily with meals for 12 weeks alongside dietary advice. Measured waist and hip circumference, abdominal fat, and inflammation, oxidative stress, lipid, liver and kidney markers. Funded by the manufacturer.
95 healthy overweight adults, 47 on Sinetrol-XPur and 48 on placebo; 12 weeks.
Waist circumference fell 5.71% versus 1.56% on placebo (p<0.0001), hip circumference 4.71% versus 1.35%, and abdominal fat 9.73% versus 3.18%. C-reactive protein fell 22.87% while rising 61% on placebo, and fibrinogen, malondialdehyde, superoxide dismutase and glutathione also moved favourably (all p<0.01). The lipid, kidney and liver panels did not change. No adverse effects were reported. Limitations: manufacturer-funded, and this is the only adequately sized trial of the ingredient.
Randomised, double-blind, crossover trial of PerfLoad, a different polyphenol product made by the same company, in 15 recreationally active men, measuring power output during high-intensity exercise after short-term dosing. It did not test Sinetrol and did not measure body weight, waist size or body fat. Funded by Fytexia.
15 recreationally active men; short-term dosing around exercise sessions.
The study reported improved exercise performance for PerfLoad. Because it tested a different product and different outcomes, it is not evidence for Sinetrol and not evidence for weight or body fat. It is listed here only for transparency about what the manufacturer has published.
Laboratory study of the Sinetrol citrus polyphenol blend on isolated human fat cells, looking at its effect on the enzyme cAMP-phosphodiesterase and on fat release. The same paper also contains a small human arm: 20 people, 10 per group, taking 1.4 g a day for 12 weeks.
Isolated human fat cells in the laboratory, plus a small human arm of 20 people (10 per group).
In the test tube, Sinetrol inhibited cAMP-phosphodiesterase by 97% and increased fat release from isolated human fat cells about six-fold compared with untreated cells. The small human arm reported body fat down 15.6% and body weight down 5.2 kg at 12 weeks, but with only 10 people per group and no clearly described placebo control, those are very large numbers from very few people and should not be taken at face value.